In this study, we demonstrated, for the first time, that the HDAC inhibitor, PBA, and its analogue, BS, promoted cardiac hypertrophy and exacerbated heart failure in response to pressure overload, which was opposite to the pan-HDAC inhibitors, TSA and VAL. This evidence concerns the gene HDAC9 and cardiac hypertrophy.